Back to Search
Start Over
Anticonvulsant Efficacy of the Low-affinity Partial Benzodiazepine Receptor Agonist ELB 138 in a Dog Seizure Model and in Epileptic Dogs with Spontaneously Recurrent Seizures.
- Source :
- Epilepsia (Series 4); Oct2004, Vol. 45 Issue 10, p1228-1239, 12p
- Publication Year :
- 2004
-
Abstract
- Purpose: Ataxia, sedation, amnesia, ethanol and barbiturate potentiation, loss of efficacy (tolerance), development of dependence, and the potential for drug abuse limit the clinical use of benzodiazepines (BZDs) for long-term treatment of epilepsy or anxiety. BZD ligands that are in current use act as full allosteric modulators of γ-aminobutyric acid (GABA)-gated chloride channels and, on long-term administration, trigger a functional uncoupling between the GABA<subscript>A</subscript> and BZD recognition sites. Partial allosteric modulators, which have a low intrinsic activity at the BZD recognition site of the GABA<subscript>A</subscript> receptor, might eventually overcome the limitations of full agonists such as diazepam (DZP). Methods: In the present study, the new low-affinity partial BZD-receptor agonist ELB 138 [former name AWD 131–138; 1-(4-chlorophenyl)-4-morpholino-imidazolin-2-one] was evaluated in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. Results: ELB 138 was shown to increase potently the pentylenetetrazole (PTZ) seizure threshold in dogs. Prolonged oral administration with twice-daily dosing of ELB 138 with either 5 or 40 mg/kg over a 5-week period was not associated with loss of anticonvulsant efficacy in the PTZ dog model. To study whether physical dependence developed during long-term treatment, the BZD antagonist flumazenil was injected after 5 weeks of treatment with ELB 138. Compared with prolonged treatment with DZP, only relatively mild abstinence symptoms were precipitated in dogs treated with ELB 138, particularly at the lower dosage (5 mg/kg, b.i.d.). In a prospective trial in dogs with newly diagnosed epilepsy, ELB 138 markedly reduced seizure frequency and severity without significant difference to standard treatments (phenobarbital or primidone) but was much better tolerated than the standard drugs, in dogs with chronic epilepsy, most dogs exhibited a reduction in seizure frequency and severity during add-on treatment with ELB 138. Conclusions: The data demonstrate that the partial BZD receptor agonist ELB 138 exerts significant anticonvulsant efficacy without tolerance in a dog seizure model as well as in epileptic dogs with spontaneously recurrent seizures. These data thus substantiate that partial agonism at the BZD site of GABA<subscript>A</subscript> receptors offers advantages versus full agonism and constitutes a valuable approach for treatment of seizures. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00139580
- Volume :
- 45
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- Epilepsia (Series 4)
- Publication Type :
- Academic Journal
- Accession number :
- 14526542
- Full Text :
- https://doi.org/10.1111/j.0013-9580.2004.21204.x